ALKS Alkermes plc.

NEUTRAL Impact: 3/10 8-K
Horizon weeks Filed May 20, 2026 Processed 20d 10h ago SEC 0001193125-26-232584
8-K context-dependent: Items 5.02
Latest settled — T+5d
ALKS ▲ +14.03% at T+5d
NEUTRAL call ✓ call won +14.03% · α vs SPY +12.18% · entry $36.79 → $41.95
Next anchor: T+20d in 8d
Last close $42.45 (close Jun 8) · +15.39% from $36.79 entry
Entry anchored
May 20, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.45%
$36.79
settled 20d ago
T+5d
+14.03%
call +14.03% · α +12.18%
$41.95
settled 13d ago
T+20d
call — · α —
in 8d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Alkermes filed an 8-K reporting results of its 2026 annual meeting, where shareholders approved an amendment to the 2018 Stock Option and Incentive Plan to increase authorized shares by 5,900,000. All director nominees were elected, and non-binding advisory votes on executive compensation and auditor ratification passed.

Actionable Insight

This is a routine governance filing with no immediate trading catalyst. Monitor future filings for actual equity grants under the expanded plan, which could indicate management's capital allocation priorities.

Key Facts

  • Shareholders approved an amendment to increase shares reserved under the 2018 Stock Option and Incentive Plan by 5,900,000.
  • All nine director nominees were elected with large majorities (e.g., Shane M. Cooke: 135.5M for, 5.5M against).
  • Say-on-pay vote passed with 139.2M for, 1.8M against.
  • Ratification of PricewaterhouseCoopers as auditor passed with 146.2M for, 2.8M against.
  • Board authority to allot shares and disapply pre-emption rights under Irish law were renewed.

Financial Impact

The 5.9M share increase represents approximately 3.5% dilution relative to the current share count, but no shares are issued immediately.

dilution

Risk Factors

  • Potential future dilution from equity grants to employees and directors.
  • No material financial or operational changes reported.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (24 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-232584
Document: alks-20260520.htm0001193125-26-232584
Document: 0001193125-26-232584-index-headers.html0001193125-26-232584
Document: 0001193125-26-232584-index.html0001193125-26-232584
Document: 0001193125-26-232584.txt0001193125-26-232584
10 reports for ALKS
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for ALKS — sortable, filterable
Type Now
Jun 4, 2026
5d ago
Insider Cluster
NEUTRAL ★ 3/10
$43.38 awaiting T+1awaiting T+1$42.45 (−2.14%)
Jun 1, 2026
8d ago
Insider Cluster
NEUTRAL ★ 2/10
$41.19 $42.71▲ +3.69%▲ +4.41%$42.45 (+3.07%)
May 20, 2026
20d ago
8-K
NEUTRAL ★ 3/10
$36.79 $36.79· 0.00%▼ −0.45%$42.45 (+15.39%)
May 13, 2026
27d ago
DEFA14A
NEUTRAL ★ 2/10
$38.26 $37.34▼ −2.40%▼ −1.18%$42.45 (+10.96%)
May 12, 2026
28d ago
8-K
BULLISH ★ 7/10
$38.26 $38.76▲ +1.31%▲ +0.73%$42.45 (+10.96%)
May 5, 2026
5w ago
8-K
MIXED ★ 5/10
$36.23 $35.19▼ −2.87%▼ −4.26%$42.45 (+17.18%)
May 1, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$33.26 $34.14▲ +2.65%▲ +2.99%$42.45 (+27.64%)
Mar 2, 2026
14w ago
Insider Cluster
NEUTRAL ★ 3/10
$30.24 $29.19▼ −3.47%▼ −2.56%$42.45 (+40.39%)
Feb 25, 2026
14w ago
8-K
MIXED ★ 6/10
$31.03 $30.75▼ −0.90%▼ −0.36%$42.45 (+36.82%)
Feb 25, 2026
15w ago
8-K
NEUTRAL ★ 4/10
$31.03 $30.75▼ −0.90%▼ −0.36%$42.45 (+36.82%)
Showing 10 of 10

US Market Status

Market Closed — Opens in 6h 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access